Search
for
Sort by
Research 961–990 of 1000+
- Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis
- Trimodal mini-invasive therapy for stable-phase Peyronie's disease: a two-center real-life prospective pilot study
- Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
- FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab
- Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study)
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Real-World, Open-Label Study of the Efficacy and Safety of a Novel Serum in Androgenetic Alopecia
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Real‐World Clinical Outcomes With a 1% SeleniumSulfide/1% Salicylic Acid Shampoo Formulation for Seborrheic Dermatitis and Dandruff: A Multicenter Observational Study
- Real-world evidence in alopecia areata treatment: A narrative review
- Real‐World Efficacy and Safety of Cuticapil Stem Hair Serum as an Add‐On to Minoxidil in Androgenetic Alopecia: A Prospective Observational Study
- “Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
- 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
- Association of Hair Loss With Health Utility Measurements Before and After Hair Transplant Surgery in Men and Women
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- Post‐finasteride syndrome: real or myth?
- Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
- Molecular insights into chronotype and time-of-day effects on decision-making